drugset / Trial / NCT06590194
PH009-1 in Patients With EGFR Mutation Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
Non-randomizedSequentialOpen-labelTreatment
Summary
The study will contain three stages: Phase I includes dose escalation phase (i.e., phase Ia) and dose expansion phase (i.e., phase Ib). Once the dosage regimen is confirmed, the sponsor can decide to start the cohort expansion phase (i.e., phase IIa)
Timeline
- Start
- 2024-09-10
- Primary completion
- 2026-06-30
- Completion
- 2026-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PH009-1 | Unknown | 75 mg | Oral |
| Subject | PH009-1 | Unknown | 150 mg | Oral |
| Subject | PH009-1 | Unknown | 300 mg | Oral |
| Subject | PH009-1 | Unknown | 450 mg | Oral |
| Subject | PH009-1 | Unknown | 600 mg | Oral |
| Subject | PH009-1 | Unknown | 750 mg | Oral |